Syntara Receives Positive FDA Feedback for Amsulostat in Myelofibrosis
Syntara, listed on the Australian Securities Exchange (ASX: SNT), has recently announced a positive outcome from its Type C meeting with the US Food and Drug Administration (FDA). This meeting provided regulatory support for the Phase 2b trial design of amsulostat, the company’s lead asset, specifically for the treatment of myelofibrosis. The news marks a significant milestone for the company as it moves forward with its development plans.
Key Highlights from the FDA Meeting
The FDA’s feedback was particularly encouraging, offering a clear path for the continued development of amsulostat. Here are some key points that emerged from the meeting:
- Positive FDA Type C Meeting: The meeting confirmed that the overall Phase 2b study design for amsulostat in myelofibrosis is aligned with the FDA’s expectations.
- Planned Phase 2b Study: Syntara intends to conduct a ~100-patient, double-blind, placebo-controlled Phase 2b study. Amsulostat will be added to standard JAK inhibition therapy, which is commonly used in the treatment of myelofibrosis.
- Primary Endpoint: The primary endpoint of the study will focus on a 50% reduction in total symptom score (TSS50) after 9 months of treatment. This endpoint provides a clear pathway into late-stage clinical development.
- Regulatory Alignment: The formal alignment with the FDA de-risks the regulatory pathway for amsulostat, enhancing its value proposition for potential partnerships. This also reinforces the drug’s differentiated status in the market.
- Existing Designations: Amsulostat already holds Fast Track and Orphan Drug Designations, which further support its development and commercial potential.
Additional Opportunities and Catalysts
Beyond the Phase 2b trial, Syntara is also advancing other studies that could add value to the company:
- Ongoing MDS Studies: Two ongoing studies focused on myelodysplastic syndromes (MDS) are currently underway, providing additional opportunities for clinical development.
- 2026 Clinical Catalysts: The company is well-positioned for multiple near-term catalysts in 2026, which could drive value creation for shareholders.
CEO Perspective
Gary Phillips, CEO of Syntara, expressed confidence in the potential of amsulostat. He described it as a potential breakthrough therapy for patients with myelofibrosis who have limited treatment options. Phillips also highlighted the importance of multiple clinical milestones across several areas, including myelofibrosis, MDS, idiopathic rapid eye movement (iRBD), and scarring. These developments are expected to make 2026 a pivotal year for the company.
Final Thoughts
While the information provided in this article is intended for informational purposes only, it is important for investors to conduct their own research and consult with certified financial advisors before making any investment decisions. The details shared here are based on the latest available information and should not be considered as investment advice.
